Department of Paediatric Haematology and Oncology, Department of Paediatric and Adolescence Medicine, Juliane Marie Center, Copenhagen University Hospital, Copenhagen, Denmark; Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Acta Oncol. 2024 May 7;63:294-302. doi: 10.2340/1651-226X.2024.27731.
Survival of children with cancer has markedly improved over recent decades, largely due to intensified treatment regimes. The intensive treatment may, however, result in fatal complications. In this retrospective cohort study, we assessed temporal variation in the incidence of treatment-related death and associated risk factors among children diagnosed with cancer in Denmark during 2001-2021.
Among all children diagnosed with first incident cancer before age 15 years recorded in the Danish Childhood Cancer Register (n = 3,255), we estimated cumulative incidence of treatment-related death (death in the absence of progressive cancer) within 5 years from diagnosis using Aalen-Johansen estimators and assessed associated risk factors using Cox regression.
Among all 3,255 children with cancer, 93 (20% of all 459 deaths) died from treatment. Of these treatment-related deaths, 39 (42%) occurred within 3 months of diagnosis. The 5-year cumulative incidences of treatment-related death were 3.3% during 2001-2010 and 2.5% during 2011-2021 (p = 0.20). During 2011-2021, treatment-related deaths accounted for more than half of all deaths among children with haematological cancers. Risk factors varied according to cancer group and included female sex, age below 1 year at diagnosis, disease relapse, stem cell transplantation, central nervous system involvement, and metastasis at diagnosis.
Despite increasing treatment intensities, the incidence of treatment-related death has remained stable during the past 20 years in Denmark. Still, clinical attention is warranted to prevent treatment-related deaths, particularly among children with haematological cancers. Patient characteristics associated with increased treatment-related death risk support patient-specific treatment approaches to avoid these fatalities.
近年来,由于治疗方案的强化,儿童癌症患者的生存率有了显著提高。然而,这种强化治疗可能导致致命的并发症。在这项回顾性队列研究中,我们评估了 2001 年至 2021 年期间丹麦诊断为癌症的儿童治疗相关死亡的发生率及其相关危险因素的时间变化。
在丹麦儿童癌症登记处记录的所有 15 岁以下首次确诊癌症的儿童(n=3255)中,我们使用 Aalen-Johansen 估计法估计了从诊断起 5 年内治疗相关死亡(在没有癌症进展的情况下死亡)的累积发生率,并使用 Cox 回归评估了相关危险因素。
在所有 3255 名癌症儿童中,有 93 人(所有 459 例死亡中的 20%)死于治疗。这些治疗相关死亡中,39 例(42%)发生在诊断后 3 个月内。2001-2010 年和 2011-2021 年治疗相关死亡的 5 年累积发生率分别为 3.3%和 2.5%(p=0.20)。在 2011-2021 年期间,治疗相关死亡占血液癌儿童所有死亡的一半以上。危险因素因癌症类型而异,包括女性、诊断时年龄小于 1 岁、疾病复发、干细胞移植、中枢神经系统受累和诊断时转移。
尽管治疗强度不断增加,但丹麦在过去 20 年中治疗相关死亡的发生率保持稳定。尽管如此,仍需临床关注以防止治疗相关死亡,特别是在血液癌儿童中。与增加治疗相关死亡风险相关的患者特征支持采用个体化的治疗方法来避免这些死亡。